scholarly journals Comparison of the survival implications of tumour-associated versus cancer-testis antigen expression in acute myeloid leukaemia

2007 ◽  
Vol 136 (3) ◽  
pp. 510-512 ◽  
Author(s):  
Barbara-ann Guinn ◽  
Khalid Tobal ◽  
Ken I. Mills
2018 ◽  
Vol 2 (01) ◽  
pp. 14-16
Author(s):  
Abul Kalam Azad ◽  
Md. Rafiquzzaman Khan ◽  
ABM Hasan Habib ◽  
Md. Abdul Wadud Miah ◽  
Masuda Begum

Background: Aberrant expression of cluster differentiation (CD) antigen marker is associated with poor outcome of acute leukaemia. Objective: Aim of this study is to determine the frequency and pattern of aberrant expression of CD markers in acute myeloid leukaemia patients in Bangladesh. Methods: This retrospective data analysis was conducted in the Department of Haematology, Bangabandhu Sheikh Mujib Medical University (BSMMU) to assess the frequency of aberrant CD antigen expression in acute myeloid leukaemia from October 2016 to September 2017. During this period, we did one hundred flow cytometry of acute leukaemia patients and among them we found 48 acute myeloid Leukaemia (AML) who were included in this study. Result: Mean age of patients was 35 years (SD­ +14 years; Rang 3 to 50 years) with male: female ratio of 0.92. Four colour flow cytometry was done on fresh bone marrow aspirates and peripheral blood. Among 48 AML patients, aberrant CD expression was observed in 58% cases.  CD5 and cCD79a lymphoid markers were seen to be expressed in 32% cases of AML. Aberrant cCD3 and CD7 were expressed in 29% and 25% cases respectively and aberrant CD10, CD19, cCD22 were expressed in 11%, 3%, 3% cases acute myeloid leukaemia patients respectively. Conclusion: Aberrant CD antigen expression is not uncommon in AML patients of Bangladeshi population that may adversely affect the treatment outcome of the disease.


2011 ◽  
Vol 86 (11) ◽  
pp. 918-922 ◽  
Author(s):  
Djordje Atanackovic ◽  
Tim Luetkens ◽  
Benjamin Kloth ◽  
Gregor Fuchs ◽  
Yanran Cao ◽  
...  

2005 ◽  
Vol 333 (3) ◽  
pp. 703-713 ◽  
Author(s):  
Barbara-ann Guinn ◽  
Amanda F. Gilkes ◽  
Eleanor Woodward ◽  
Nigel B. Westwood ◽  
Ghulam J. Mufti ◽  
...  

2018 ◽  
Vol 71 (12) ◽  
pp. 1051-1059
Author(s):  
Katelyn C Dannheim ◽  
Olga Pozdnyakova ◽  
Paola Dal Cin ◽  
Olga K Weinberg

AimsCytogenetic and molecular aberrations are the strongest factors in determining outcome in acute myeloid leukaemia (AML). AML with complex karyotype confers a particularly poor prognosis and is associated with morphologic dysplasia. Flow cytometric immunophenotyping (FCI) has been investigated in defining dysplasia within myelodysplastic syndromes, but little is known about immunophenotypic dysplasia in AML and correlation with genetic abnormalities. This study aimed to explore differences in antigen expression by FCI in AML with complex karyotype (AML-CK) and AML with complex karyotype and TP53 mutations (AML-TP53) compared with AML with normal karyotype (AML-NK).MethodsTwenty-five cases of AML-CK, 13 of which had abnormalities of TP53, were compared with 83 cases of AML-NK using FCI.ResultsOur findings demonstrated brighter expression of CD34 with decreased CD33 and aberrant expression of CD5 in blasts of AML-CK, while AML-TP53 blasts exhibited brighter expression of CD13. Granulocytes in AML-CK exhibited brighter expression of CD5, CD7, CD10 and CD14, with brighter CD3 also seen in AML-TP53.ConclusionsOur results suggest that immunophenotypic dysplasia correlates with complex karyotype and TP53 mutation, including increased expression of T-cell antigens.


Oncotarget ◽  
2016 ◽  
Vol 7 (11) ◽  
pp. 12840-12856 ◽  
Author(s):  
Pragya Srivastava ◽  
Benjamin E. Paluch ◽  
Junko Matsuzaki ◽  
Smitha R. James ◽  
Golda Collamat-Lai ◽  
...  

2019 ◽  
Vol 19 (4) ◽  
pp. 233-234
Author(s):  
Jorrit Schaefer ◽  
Sorcha Cassidy ◽  
Rachel M. Webster

Sign in / Sign up

Export Citation Format

Share Document